The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon gamma as a therapeutic agent to restore retinal fluid absorption.

This technology includes the use of Interferon gamma to restore fluid absorption in retinal pigment epithelial (RPE) cells, specifically targeting the adverse effects of fluid accumulation under the retina caused by small molecule cancer therapeutic drugs like Meki. The problem arises when cancer treatments, particularly MAP Kinase/ERK Kinase Inhibitors, lead to unwanted fluid build-up, which can impair vision and overall retinal health. This technology addresses a significant challenge in ocular health by providing a potential therapeutic solution to mitigate these side effects of cancer treatment.

The technical solution involves leveraging the previously established method of fluid transport across RPE cells, enhanced by the application of Interferon gamma. This approach not only aims to alleviate fluid accumulation but also seeks to improve the overall efficacy of cancer therapies by minimizing their ocular side effects. You should care about this technology because it represents a novel intersection of oncology and ophthalmology, potentially improving patient outcomes for those undergoing cancer treatment.

Currently, the National Eye Institute (NEI) is seeking collaborative support to fund or provide a source of Interferon gamma for larger clinical trials. There is an opportunity for licensing this technology, especially as NEI is in discussions with potential partners, including a start-up and Merck, to further clinical trials related to this innovative approach. This presents a unique chance for collaboration and investment in a promising therapeutic avenue.